Abzu

📍 Nordhavn, Denmark🗓 Founded 2018👥 25 employees💰 Last funded Apr 2021
Biotechnology Research🌐 abzu.ai
Website LinkedIn
Abzu is the best in class in silico disease understanding and drug design company. Since its founding in 2018, Abzu’s proprietary explainable AI, the QLattice®, has been the cornerstone to their cutting-edge approach. Abzu is a preferred partner for pharma, biotech, and research institutions, transforming data into insights and accelerating R&D. Abzu has offices in Copenhagen and Barcelona, and has raised €13.3M in total funding to date. Abzu has been mentioned in Gartner® research, from Market Guides for AI Trust, Risk, and Security Management to Cool Vendor™, and is the winner of several awards, including the 2023 “Best HealthTech” Nordics Award at the Nordic Startup Awards.
4
Total investors
2
Early stage
2
Mid stage
0
Late stage
2018
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Denmark
4
Investor activity2018–2021 · investors recorded per year
201812019120212
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Abzu?
Abzu has 4 investors on record on gritt.io, including 2 early-stage backers, 2 mid-stage.
When did Abzu last raise funding?
The most recent investment in Abzu recorded on gritt.io was in April 2021.
When was Abzu founded?
Abzu was founded in 2018.
What industry is Abzu in?
Abzu operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Abzu based?
Abzu is headquartered in Nordhavn, Denmark.